N-{[6-Amino-4-(methylthio)pyridin-2-yl]carbamoyl}-5-(2-methoxyethyl)-4-methylthiophene-2-sulfonamide | 1158785-38-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-{[6-Amino-4-(methylthio)pyridin-2-yl]carbamoyl}-5-(2-methoxyethyl)-4-methylthiophene-2-sulfonamide
• 英文别名: N-(6-amino-4-(methylthio)pyridin-2-ylcarbamoyl)-5-(2-methoxyethyl)-4-methylthiophene-2-sulfonamide；1-(6-amino-4-methylsulfanylpyridin-2-yl)-3-[5-(2-methoxyethyl)-4-methylthiophen-2-yl]sulfonylurea
• CAS: 1158785-38-6
• 化学式: C₁₅H₂₀N₄O₄S₃
• 分子量: 416.546
• InChiKey: HAFPBJXRPVPNLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  185
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-溴-3-甲基噻吩 在 氯化亚砜 、 三氧化硫 、 氨 、 magnesium 作用下， 以 四氢呋喃 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-{[6-Amino-4-(methylthio)pyridin-2-yl]carbamoyl}-5-(2-methoxyethyl)-4-methylthiophene-2-sulfonamide
  参考文献：
  名称：

  Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase

  摘要：

  A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.044

文献信息

• NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES
  申请人：Haap Wolfgang

  公开号：US20090143439A1

  公开（公告）日：2009-06-04

  Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.

  式(I)的化合物以及其药用可接受的盐和酯，其中残基具有在权利要求1中给出的意义，并且可以用作药物组合物的形式。
• PYRIDINE COMPOUNDS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2227452A2

  公开（公告）日：2010-09-15
• US8163778B2
  申请人：——

  公开号：US8163778B2

  公开（公告）日：2012-04-24
• [EN] PYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009068468A2

  公开（公告）日：2009-06-04

  Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
• Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase
  作者：Paul Hebeisen、Wolfgang Haap、Bernd Kuhn、Peter Mohr、Hans Peter Wessel、Ulrich Zutter、Stephan Kirchner、Armin Ruf、Jörg Benz、Catherine Joseph、Rubén Alvarez-Sánchez、Marcel Gubler、Brigitte Schott、Agnes Benardeau、Effie Tozzo、Eric Kitas

  DOI：10.1016/j.bmcl.2011.04.044

  日期：2011.6

  A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase. (C) 2011 Elsevier Ltd. All rights reserved.